Albumin dialysis in cirrhosis with superimposed acute liver injury: Possible impact of albumin dialysis on hospitalization costs

Liver International

Volumn 23, Issue SUPPL. 3, 2003, Pages 61-65

  Hassanein, T ^a   Oliver, D ^a   Stange, J ^a   Steiner, Christian ^b  

^a UCSD MEDICAL CENTER   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Alcoholic hepatitis; Artificial liver; Cost effectiveness

Indexed keywords

ALBUMIN;

ALCOHOL LIVER CIRRHOSIS; ARTICLE; CALCULATION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPLICATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DEATH; DISEASE ASSOCIATION; HEMODIALYSIS; HOSPITAL COST; HOSPITAL RUNNING COST; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LIVER INJURY; MEDICAL CARE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; STANDARD; SURVIVAL; TREATMENT OUTCOME;

EID: 0141960399     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1478-3231.23.s.3.6.x     Document Type: Article

References (27)

1. Kamath P S, Wiesner R H, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-70.
2. Knaus W A, Draper E A, Wagner D P, Zimmerman J E. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-29.
3. Zimmerman J E, Wagner D P, Seneff M G, Becker R B, Sun X, Knaus W A. Intensive care unit admissions with cirrhosis: risk-stratifying patient groups and predicting individual survival. Hepatology 1996; 23: 1393-401.
4. Singh N, Gayowski T, Wagener M M, Marino I R. Outcome of patients with cirrhosis requiring intensive care unit support: prospective assessment of predictors of mortality. J Gastroenterol 1998; 33: 73-9.
5. Maddrey W C. Bioartificial liver in the treatment of hepatic failure. Liver Transpl 2000; 6: S27-30.
6. Allen J W, Hassanein T, Bhatia S N. Advances in bioartificial liver devices. Hepatology 2001; 34: 447-55.
7. Ash S R, Blake D E, Carr D J, Carter C, Howard T, Makowka L. Clinical effects of a sorbent suspension dialysis system in treatment of hepatic coma (the BioLogic-DT). Int J Artif Organs 1992; 15: 151-61.
8. Hughes R D, Williams R. Assessment of bioartificial liver support in acute liver failure. Int J Artif Organs 1996; 19: 3-6.
9. Mitzner S R, Stange J, Klammt S, Peszynski P, Schmidt R, Noldge-Schomburg G. Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure. J Am Soc Nephrol 2001; 12: S75-82.
10. Sen S, Mookerjee R P, Davies N A, Williams R, Jalan R. Review article: the Molecular Adsorbents Recirculating System (MARS) in liver failure. Aliment Pharmacol Ther 2002; 16: 32-8.
11. Stange J, Mitzner S, Ramlow W, Gliesche T, Hickstein H, Schmidt R. A new procedure for the removal of protein bound drugs and toxins. Asaio J 1993; 39: M621-5.
12. Stange J, Mitzner S. A carrier-mediated transport of toxins in a hybrid membrane. Safety barrier between a patients blood and a bioartificial liver. Int J Artif Organs 1996; 19: 677-91.
13. Mitzner S, Stange J, Freytag J, Lindemann S, Schmidt R. Role of transport proteins in bioartificial liver assist systems. Int J Artif Organs 1996; 19: 49-52.
14. Lamesch P, Jost U, Schreiter D, et al. Molecular adsorbant recirculating system in patients with liver failure. Transplant Proc 2001; 33: 3480-2.
15. Jalan R, Sen S, Steiner C, Kapoor D, Alisa A, Williams R. Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis. J Hepatol 2003; 38: 24-31.
16. Novelli G, Rossi M, Pretagostini R, et al. Use of MARS in the treatment of acute liver failure: preliminar monocentric experience. Transplant Proc 2001; 33: 1942-4.
17. Novelli G, Rossi M, Pretagostini R, et al. MARS (Molecular Adsorbent Recirculating System): experience in 34 cases of acute liver failure. Liver 2002; 22: 43-7.
18. Schmidt L E, Sorensen V R, Svendsen L B, Hansen B A, Larsen F S. Hemodynamic changes during a single treatment with the molecular adsorbents recirculating system in patients with acute-on-chronic liver failure. Liver Transpl 2001; 7: 1034-9.
19. Schmidt L E, Svendsen L B, Sorensen V R, Hansen B A, Larsen F S. Cerebral blood flow velocity increases during a single treatment with the molecular adsorbents recirculating system in patients with acute on chronic liver failure. Liver Transpl 2001; 7: 709-12.
20. Sorkine P, Ben Abraham R, Szold O, et al. Role of the molecular adsorbent recycling system (MARS) in the treatment of patients with acute exacerbation of chronic liver failure. Crit Care Med 2001; 29: 1332-6.
21. Stange J, Mitzner S R, Klammt S, et al. Liver support by extracorporeal blood purification: a clinical observation. Liver Transpl 2000; 6: 603-13.
22. Stange J, Mitzner S R, Risler T, et al. Molecular Adsorbent Recycling System (MARS): clinical results of a new membrane-based blood purification system for bioartificial liver support. Artif Organs 1999; 23: 319-30.
23. Mitzner S R, Stange J, Klammt S, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000; 6: 277-86.
24. Heemann U, Treichel U, Loock J, et al. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 2002; 36: 949-58.
25. Mitzner S R, Klammt S, Peszynski P, et al. Improvement of multiple organ functions in hepatorenal syndrome during albumin dialysis with the molecular adsorbent recirculating system. Ther Apher 2001; 5: 417-22.
26. Sen S, Jalan R, Williams R. Extracorporeal albumin dialysis in acute-on-chronic liver failure: will it stand the test of time? Hepatology 2002; 36: 1014-6.
27. Kim W R, Gross J B, Jr, Poterucha J J, Locke G R, 3rd, Dickson E R. Outcome of hospital care of liver disease associated with hepatitis C in the United States. Hepatology 2001; 33: 201-6.